Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Endocrine 1

Conditions

Carcinoma, Renal Cell 16Prostatic Neoplasms 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Neoplasms 3Urogenital Neoplasms 2Ureteral Neoplasms 2Sarcoma, Ewing 2Penile Neoplasms 2Osteosarcoma 2Neuroendocrine Tumors 2Melanoma 2Lung Neoplasms 2Kidney Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Central Nervous System Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Medullary 2Carcinoma 2Adrenocortical Carcinoma 2von Hippel-Lindau Disease 1Wilms Tumor 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1fluorodopa F 18 1cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × cabozantinib × 30 days × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡